Llorca, P. M.
Pereira, B.
Jardri, R.
Chereau-Boudet, I.
Brousse, G.
Misdrahi, D.
Fénelon, G.
Tronche, A.-M.
Schwan, R.
Lançon, C.
Marques, A.
Ulla, M.
Derost, P.
Debilly, B.
Durif, F.
de Chazeron, I.
Article History
Received: 5 September 2016
Accepted: 4 November 2016
First Online: 1 December 2016
Competing interests
: Author Llorca P.-M. reports grants from Lilly, personal fees from Janssen, nonfinancial support from Roche, and grants from Otsuka, all outside the submitted work. Author Renaud Jardri reports personal fees for lectures: Lundbeck, Astra-Zeneca, Janssen-Cilag, Otsuka pharmaceutical, Shire and GlaxoSmithKline, all outside of the submitted work Author Brousse G. reports personal fees from Lundbeck, Janssen-Cilag and Otsuka pharmaceutical, all outside of the submitted work. Author Fénelon G. reports personal fees from Lundbeck and Teva Pharma, all outside the submitted work. Author Schwan R. reports grants from Boucharad and personal fees from Lundbeck, Janssen-Cilag, Otsuka pharmaceutical and Reckitt-Bekinson, all outside of the submitted work. Author Durif F. reports grants from CHU Clermont Ferrand, during the conduct of the study; grants from Novartis SA, Lundbeck, and Merz; and personal fees from Novartis SA, Lundbeck, Allergan, Aguettant, Teva Pharma, and Servier, all outside the submitted work. All other authors declare that they have no conflicts of interest.